COR
Cencora, Inc.
COR's fundamentals are mixed: free cash flow more than tripled, while its operating margin held steady at 0.9%. At 26x earnings, it's trading in line with its usual 24x. Analysts expect earnings growth.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
COR Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Stable | |
| Stable |
COR's profitability is currently healthy, and its revenue, cash flow and balance sheet are stable.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
COR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 18x | $237 | -32% |
| Forward | 18x | $349 | — |
| Fair | 24x | $320 | -8.3% |
| Current | 26x | $349 | — |
| Expensive | 33x | $450 | +29% |
Historical ranges are pointers, not guarantees.
COR's PE is in its expensive range at 26x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
COR Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Stable | |
| Stable | |
| Limited | |
| High |
Analysts expect COR's earnings to grow, with its revenue and profitability holding steady.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
COR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $19.77 | +47% |
| Q2 2026 | $13.47 | +38% |
| Q1 2026 | $13.05 | +51% |
| Q4 2025 | $8.33 | +18% |
| Q3 2025 | $7.96 | +5.7% |
| Q2 2025 | $9.74 | +5.8% |
| Q1 2025 | $8.64 | -5.5% |
| Q4 2024 | $7.05 | -23% |
| Q3 2024 | $7.53 | -12% |
COR has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
COR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $84.8B | +5.1% |
| Q1 2026 | $78.4B | +3.8% |
| Q4 2025 | $85.9B | +5.5% |
| Q3 2025 | $83.7B | +5.9% |
| Q2 2025 | $80.7B | +8.7% |
| Q1 2025 | $75.5B | +10% |
| Q4 2024 | $81.5B | +13% |
| Q3 2024 | $79.1B | +15% |
COR's revenue has grown year over year every quarter since late 2020: $84.8B last quarter, up 5.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 1.3% | +0.2 points |
| Q1 2026 | 1.5% | +0.1 points |
| Q4 2025 | 0.9% | 0 points |
| Q3 2025 | 0% | -0.1 points |
| Q2 2025 | 1.1% | +0.2 points |
| Q1 2025 | 1.4% | +0.6 points |
| Q4 2024 | 0.9% | -0.3 points |
| Q3 2024 | 0.2% | -0.5 points |
COR has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over COR on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
COR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $2.4B | +$2.5B |
| Q1 2026 | $1.2B | -64% |
| Q4 2025 | -$2.4B | +$400.1M |
| Q3 2025 | $2.9B | +252% |
| Q2 2025 | -$74M | -103% |
| Q1 2025 | $3.2B | +$4.2B |
| Q4 2024 | -$2.8B | -448% |
| Q3 2024 | $818.1M | -50% |
COR generated $4.1B in free cash flow over the past year, about four times what it generated the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over COR on cash flow, with more consistent year-over-year improvement.
COR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.7% | -1.4M shares |
| 1 year | -0.7% | -1.3M shares |
| 3 years | -5.1% | -10.4M shares |
| 5 years | -7.2% | -15M shares |
| Available history | -8.4% | -17.9M shares |
COR has 194M diluted shares, down 0.7% from a year ago, with $1B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q2 2026 | $1B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | $71,000 |
| Q2 2025 | — |
| Q1 2025 | $50M |
| Q4 2024 | $385.4M |
| Q3 2024 | $505M |
COR spent $1B buying back its own shares over the past year, up 6.4% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over COR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
COR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 2.2x | Moderate |
| Q1 2026 | 2.7x | Moderate |
| Q4 2025 | 1.7x | Healthy |
| Q3 2025 | 0.9x | Very low |
| Q2 2025 | 1.6x | Healthy |
| Q1 2025 | 1.6x | Healthy |
| Q4 2024 | 1.6x | Healthy |
| Q3 2024 | 0.4x | Very low |
COR's net debt is about 2.2 years of its operating earnings (EBITDA), up from 1.6 years a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has the edge over COR on leverage, with a lower net debt burden relative to earnings.
COR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 63.7 | Neutral |
| Stochastic | 68.6 | Neutral |
COR's weekly RSI is 64 (neutral) and its Stochastic is 69 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
COR PE vs Healthcare Sector
| Metric | COR | Sector median | Relative |
|---|---|---|---|
| PE | 26x | 26x | 0.3% above |
| PE % | 68 | 29 | 39 pts above |
COR is trading at 26x earnings, in line with the Healthcare sector's median of 26x.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
COR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $328.2 | 6.5% above |
| 20 week MA | $319.5 | 9.3% above |
| 50 week MA | $321.3 | 8.7% above |
| 100 week MA | $304.2 | 15% above |
| 200 week MA | $255.0 | 37% above |
COR has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
COR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $84.9 | $97.0 | +14% |
| 2021 | $97.0 | $129.5 | +34% |
| 2022 | $129.5 | $170.0 | +31% |
| 2023 | $170.0 | $205.4 | +21% |
| 2024 | $205.4 | $226.9 | +10% |
| 2025 | $226.9 | $341.1 | +50% |
| 2026 YTD | $341.1 | $349.4 | +2.4% |
COR has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.